Should you be screened for type 2 diabetes?

US preventive-health guidelines recommend that adults aged 35 to 70 who have overweight or obesity be screened for prediabetes and type 2 diabetes, even without symptoms [s1]. The main specialist body, the American Diabetes Association, casts a wider net, advising a test for every adult starting at age 35 [s2] — and that gap is really a disagreement about where the benefit of catching disease early stops outweighing the downside of testing people who are well.

Screening means testing someone with no symptoms in the hope of finding a condition before it declares itself. Type 2 diabetes is a natural candidate because it builds silently: blood sugar can run high for years, quietly damaging blood vessels, before thirst, fatigue or blurred vision appear. In the United States an estimated 13% of adults have diabetes and 34.5% meet the criteria for prediabetes, and diabetes is the leading cause of kidney failure and of new blindness in adults, as well as the seventh leading cause of death recorded in 2017 [s1]. The case for looking early almost writes itself. The catch is that screening only helps if finding the condition sooner leads to something that improves outcomes, and if the harms of testing everyone stay small.

What the US Preventive Services Task Force recommends

The US Preventive Services Task Force, an independent expert panel, gives screening a "B" grade — meaning it found moderate certainty of a moderate net benefit — but only for a defined group: non-pregnant adults aged 35 to 70 years who have overweight or obesity, defined as a body-mass index of 25 or more, or 30 or more, respectively [s1]. That 2021 statement lowered the starting age from 40 in its previous 2015 version [s1]. For people whose first test is normal, it notes that re-screening every three years may be a reasonable interval [s1].

Two nuances matter. The Task Force advises considering screening earlier, or at a lower weight threshold, in groups with higher risk at a given body size — including American Indian/Alaska Native, Black, Hispanic/Latino, and Native Hawaiian/Pacific Islander adults, and Asian American adults at a BMI of 23 or above [s1]. And, importantly, it framed the benefit as coming not from the blood test itself but from what follows a positive one: referring people found to have prediabetes to effective preventive programmes, chiefly intensive lifestyle interventions [s1]. A screen that is not connected to that follow-up does little.

Where the diabetes specialists go further

This is a case where the disease specialists would screen more people than the preventive panel endorses. The American Diabetes Association's 2026 Standards of Care recommend testing all adults beginning at age 35, regardless of weight, and testing at any age in adults with overweight or obesity who have an additional risk factor, such as a family history or high blood pressure [s2]. The tests are the same in both frameworks — a glycated haemoglobin (HbA1c), a fasting plasma glucose, or an oral glucose-tolerance test — and the diagnostic lines are shared: an HbA1c of 6.5% or higher signals diabetes, while 5.7% to 6.4% marks prediabetes [s2]. (What that percentage does and does not capture is covered in our explainer on the A1c number.)

The divergence, then, is about the width of the net, not the cut-off. The Task Force restricts a positive recommendation to the group where trial evidence most clearly shows the benefits beat the harms — older, heavier adults — and stays silent rather than positive elsewhere. The ADA, weighing the same disease against the ease and low cost of a blood test, would rather not miss the leaner or younger person whose diabetes is building unseen.

The case for caution

The reason a wider net is not automatically better is that screening asymptomatic people carries its own costs. It generates false positives and borderline results that lead to repeat testing and anxiety; it can attach a "prediabetes" label to people, many of whom will never progress to diabetes; and its whole value depends on the health system actually delivering the lifestyle support that makes early detection worthwhile [s1]. Estimates of how many people with prediabetes go on to develop diabetes vary widely, partly because the definition itself is broad [s1]. None of that argues against screening the groups where the evidence is strong — it argues for being clear-eyed that the test is a first step, valuable only if it is wired to effective follow-up.

What it means for a reader

Whether a screening test is worthwhile turns on age, weight and individual risk rather than on general worry, and the two main guidelines agree far more than they differ: both would test an older adult carrying extra weight, and both treat the same numbers as the threshold for disease [s1] [s2]. The live question — test everyone from 35, or only those at higher risk — is a genuine judgement call about population benefit, of the same kind that governs who benefits from screening for an aortic aneurysm or a coronary calcium scan. It bears on the rising burden of early-onset type 2 diabetes, and the payoff depends on connecting a positive test to proven prevention programmes; the broader shifts in diabetes practice are tracked in the 2026 ADA standards. This is informational, not medical advice: whether and when to be tested is a decision to make with a clinician.